

103 the control of vaginal homeostasis, depending on the presence and absence of estrogen.

104

105 **Results**

106 *Effect of epithelial cell-specific inactivation of Pten on the mouse vagina*

107 CK5 is generally expressed in the stratified and squamous epithelium¹⁷.
108 Hence, *Pten* CKO induced by *CK5-Cre*-mediated deletion progressively developed
109 hyperplasia and keratosis in the stratified and keratinized organs, which include
110 epidermis of the skin, tongue, esophagus and forestomach (Fig. S1). We first explored
111 whether *Pten* CKO induced hyperplasia and/or hyperkeratinization in the vagina as well.
112 The epithelial cell-specific expression of Cre in the *K5-Cre* line was confirmed Rosa
113 reporter mouse (Fig. S2). Accordingly, the epithelium-specific deletion of *Pten* was
114 evident in the *Pten* CKO mouse vagina (Fig. 1; Note that stromally expressed Pten is
115 still evident). In the current study, OVX mice were used to avoid any effects of
116 hypothalamus-pituitary-gonadal axis, and to simply analyze the effects of
117 Pten/PI3K/Akt in the absence of estrogen signaling (all information for intact *Pten* CKO
118 phenotypes are included in Fig. S3).

119 The vaginal epithelium of 8-week-old ovariectomized (OVX) mice (control)
120 was composed of 1-2 layers of cuboidal cells (Fig. 2A). In the CKO mice, epithelial
121 hyperplasia was evident, which was accompanied with distended cells in the superficial
122 layer of the vagina (Fig. 2B, B'). We also found multiple abnormal gland-like pits in the
123 epithelium. The epithelial cells lining the pits were positive for PAS and Alcian blue
124 staining (Fig. 2C-F), indicating mucin production. Such mucin production was observed
125 restrictedly in the superficial layer of cells, but not in the basal cells, of the vaginal
126 epithelium. PAS and Alcian blue positive cells were limited in the superficial layer of
127 the control vaginae. Thus, the phenotypes of *Pten* CKO mice probably result from
128 defects in the control of epithelial cell proliferation and differentiation, causing

129 increased mucin production in epithelial cells. Intriguingly, E2 administration in *Pten*
130 CKO mice induced stratification and keratinized differentiation in the vaginal
131 epithelium comparable to that in E2-treated controls (Fig. 2G, H). The epithelium in the
132 *Pten* CKO mice administrated with E2 is thicker than that of controls (Fig. 2I). PAS and
133 Alcian blue positive cells were not observed in E2-treated control or *Pten* CKO mouse
134 vagina (data not shown). At 2 weeks after the last E2 administration, *Pten* CKO mouse
135 vaginae exhibited a recurrence of the abnormal phenotypes (Fig. 2J), thus the vaginal
136 changes in the *Pten* CKO mouse are dependent on the absence of estrogen. We also
137 investigated the effects of a prolonged E2 exposure. Two months after implantation with
138 E2 pellet, *Pten* CKO mice exhibited frequent invagination of the vaginal epithelium into
139 underlying stroma (Fig. 2K, L), which might be associated with tumor formation later in
140 life⁴.

141

142 *Cell differentiation in the Pten CKO mouse vaginal epithelial cells*

143 To further characterize the phenotypes of the *Pten* CKO mouse vagina,
144 several immunohistochemical stainings were performed. CK14 is a whole epithelial
145 marker in the vagina¹⁸. In both control and *Pten* CKO mice, CK14 was expressed
146 throughout all layers of the vaginal epithelium (Fig. 3A, B). In the control OVX mice,
147 the stratified and squamous differentiation marker, CK1 was expressed in several
148 suprabasal cells, whereas its expression was not observed in the OVX *Pten* CKO mice
149 (Fig. 3C, D). CK8 is a marker for undifferentiated cells and was expressed in some
150 suprabasal cells in the control OVX mouse vaginae (Fig. 3E). Intriguingly, CK8 was
151 strongly expressed in the OVX *Pten* CKO mouse vagina (Fig. 3F). We infer from these
152 results that suprabasal cells in the *Pten* CKO mouse vaginae are maintained an

153 undifferentiated, proliferating state. p63 is normally expressed in the basal layer of the
154 epithelium and is a crucial regulator of squamous differentiation^{19,20}. p63 was
155 expressed in cells adjacent to the basement membrane in OVX control mice, whereas its
156 expression in OVX *Pten* CKO mice was not restricted in the basal cells and was
157 observed some suprabasal cells away from the basement membrane (Fig. 3G, H).

158 After E2-administration, these marker proteins were similarly expressed in
159 both control and the mutant mouse vagina (Fig. 3I-N), but p63 expression in mutant
160 animals was more extensive in the upper layers (Fig. 3O, P).

161

162 *Cell proliferation, but not apoptosis is increased in the Pten CKO mouse vaginae*

163 We next investigated the proliferation indices of vaginal epithelial cells in
164 control and *Pten* CKO mice using BrdU incorporation. Proliferation indices were higher
165 in the OVX CKO than in OVX controls (Fig. 4A, B, E). In both control and mutants,
166 BrdU-positive cells were mostly found adjacent to or attached to the basement
167 membrane but some cells in the upper layer were positive for BrdU staining (red
168 arrowheads in Fig. 4B) in the *Pten* CKO mouse vagina. Three-successive
169 administrations of E2 strongly stimulated cell proliferation in both control and *Pten*
170 CKO mice (Fig. 4C, D, E).

171 We also examined whether reduced apoptosis in the epithelial cell contributed
172 to the phenotypes in the *Pten* CKO mouse vagina. Apoptotic indices as measured by
173 TUNEL staining did not differ significantly between control and mutant vaginal
174 epithelia (Fig. 4F-H). Apoptotic cells were almost undetectable in the vagina of E2
175 treated control and mutant mice (data not shown). These results indicate that *Pten*
176 loss-of-function enhanced cell proliferation in the OVX mice but not significantly alter

177 apoptosis.

178

179 *Activation of mTOR and MAPK pathway in the mutants*

180 To identify potential molecular mechanisms that could lead to abnormal cell
181 proliferation and differentiation in the vaginal epithelium, we examined
182 phosphorylation levels of known downstream effector of the Akt signaling pathway,
183 mammalian target of rapamycin (mTOR)²¹⁻²³. As expected, enhanced Akt
184 phosphorylation was observed in the mutant mouse vagina (Fig. 5A, B). In addition,
185 mTOR phosphorylation was significantly increased in *Pten* mutant vaginae (Fig. 5A, B).
186 To explore the contribution of mTOR to the mutant phenotype, rapamycin, a specific
187 inhibitor of mTOR, was administrated to control and *Pten* CKO OVX mice. Rapamycin
188 administration for 3 weeks resulted in regression of cells in the suprabasal layer of most
189 part of the vagina, although mucus-like products still remained (Fig. 5C-F). Levels of
190 cell proliferation in mutant rapamycin-treated group were slightly increased compared
191 to control rapamycin-treated mice (Fig. 5G). Importantly, the index in the mutants with
192 rapamycin was reduced by half (5.1% vs. 10.3%), compared with that of OVX *Pten*
193 CKO mice without rapamycin (Fig. 5G). Rapamycin administration did not influence
194 on the Akt phosphorylation (Fig. 5H), indicating specific inhibition of mTOR complex
195 1 pathway. These results indicate that increased cell proliferation in *Pten* mutant vaginal
196 epithelium at least partly requires the mTOR pathway.

197 Activation of MAPK has been implicated for mucin production in the
198 respiratory tract, intestine and prostate²⁴⁻²⁶. Indeed, we observed increased expression
199 of phosphorylated mitogen-activated protein kinase (MEK) and extracellular
200 signal-regulated kinase (ERK1/2) in the suprabasal cells from *Pten* CKO animals (Fig.

201 6A-D). Activated MAPK remained in the *Pten* CKO mice administrated with rapamycin
202 (Fig. 6E, F), supporting the fact that rapamycin did not repress mucin production (Fig.
203 5D, F).

204 It is known that activated MAPK and/or Akt can stimulate the transcriptional
205 activity of ER α (in a ligand-independent manner) by phosphorylating serines 118 and
206 167 of this receptor (located within the AF-1 region), respectively²⁷⁻²⁹. ER α protein
207 was observed in the vaginal epithelium and stroma of both control and *Pten* CKO
208 animals (Fig. 6G, H). Both residues of the ER α were phosphorylated in the *Pten* CKO
209 compared with control animals (Fig. 6I). On the other hand, expression of growth factor
210 mRNAs that are considered to be targets of ER α ⁸ was not significantly changed
211 between controls and *Pten* CKO mice (Fig. 6J). Although, phosphorylation of ER α has
212 been implicated in estrogen-independent cell proliferation and differentiation^{8,9}, these
213 results suggest that phenotypes induced by *Pten* loss-of-function are independent of
214 ER α signaling.

215

216 *Estrogen-dependent localization of phosphorylated Akt in mouse vagina*

217 Lastly, we examined potential differences in *Pten* function among several
218 stratified and squamous epithelia in mice. Numerous studies have shown that *Pten*
219 exerts its tumor suppressive function through inhibition of Akt activation; therefore, it is
220 generally believed that a major *Pten* function is regulation of cell proliferation in such
221 organs. We found that *Pten* is mainly expressed in the basal cells in stratified and
222 squamous epithelia, such as epidermis of the skin, tongue, esophagus and forestomach,
223 although *Pten* expression levels vary among these tissues (Fig. 7A-D). Consequently,

224 the deletion of *Pten* augmented the phosphorylation of Akt in the corresponding regions
225 of the epithelia in the *Pten* CKO mice (Fig. 7E-H).

226 The stratified and keratinized vagina of control mice administrated with E2
227 expressed Pten predominantly in the basal cells as well (See Fig. 1A). Concomitantly,
228 phospho-Akt was detected in the lower layers of epithelia including basal cells in the
229 control (Fig. 7I) and was augmented throughout the epithelium, particularly in the basal
230 to suprabasal cell layers in the *Pten* CKO mice (Fig. 7J). Intriguingly, in the OVX
231 control mice, Pten was exclusively expressed in the suprabasal cells (See Fig. 1B). The
232 phosphorylated Akt was not detected in the OVX control mice (Fig. 7K). When *Pten*
233 was deleted, phospho-Akt was found in the suprabasal cells but not in the basal cells
234 (Fig. 7L). Thus, Pten expression and its regulation of Akt in the mouse vagina depend
235 on the presence or absence of estrogen, and this might explain the unique phenotypes of
236 the *Pten* CKO mouse vagina.

237

238 **Discussion**

239 Estrogens play a central role in female reproductive organ biology. Despite
240 the importance of this organ system for fertility and women's health, the signaling
241 pathways that regulate cell proliferation and differentiation remain poorly understood.
242 *Pten* tumor-suppressor gene lipid phosphatase activity acts in opposition to PI3K
243 function and *Pten* loss-of-function mutations frequently result in sporadic and
244 hereditary cancers accompanied by Akt activation^{1,4,30}. Akt was shown to be
245 phosphorylated as a result of estrogen treatment and was described as a functional
246 mediator of estrogen-induced cell proliferation and differentiation in mouse uterus and
247 vagina^{9,31}. Therefore, Akt signaling is currently thought to be an essential mediator for
248 estrogen-induced events. If this is the case, activation of Akt, *per se*, should result in cell
249 proliferation and squamous differentiation in the mouse vaginal epithelium even in the
250 absence of estrogen. To test this hypothesis, we utilized an epithelial cell-specific
251 conditional *Pten* knock-out mice.

252 First, we expected cell proliferation and squamous hyperplasia in the vaginal
253 epithelium, because *Pten* mutation results in squamous hyperplasia and tumor formation
254 in other stratified and squamous tissues such as skin, esophagus and stomach¹. Despite
255 the intrinsic similarity among such differentiated stratified, squamous epithelia, the
256 phenotypes observed in the *Pten* CKO mouse vagina are unique. Cell proliferation in
257 the *Pten* CKO mouse vaginal epithelium is indeed increased, however, a remarkable
258 hyperplasia was observed in the suprabasal cells accompanied with abnormal mucin
259 production. Based on the CK1, CK8 and p63 expression pattern, the suprabasal cells in
260 the *Pten* CKO mice are maintained in a largely undifferentiated condition. We infer that
261 the suprabasal cells in the *Pten* CKO mice fail to completely differentiate into squamous

262 cells and retain an undifferentiated status with the potential for cell proliferation.
263 Immunohistochemical analysis in OVX control mouse vaginae revealed the unique
264 expression of *Pten* in the suprabasal layers. Hence, the primary role for *Pten* in the
265 mouse vagina seems to block aberrant cell proliferation in the suprabasal cells rather
266 than to control basal cell proliferation in the absence of estrogen.

267 It was unknown whether the vaginae in the OVX *Pten* CKO mouse develop
268 tumors. It has been reported that 90% of OVX *Pten* heterozygote mice developed
269 uterine epithelial hyperplasia³². This suggests that *Pten* loss-of-function is sufficient for
270 the development of complex atypical hyperplasia (CAH) in the absence of estrogen.
271 Since CAH often precedes endometrial carcinoma³², this may be consistent with a role
272 for *Pten* in vaginal cancers. Therefore, we could not exclude the possibility of
273 spontaneous tumorigenesis in the *Pten* CKO mouse vagina without estrogenic
274 stimulation. Several lines of epithelial cell-specific *Pten* mutants have shown decreased
275 survival rate with severe growth retardation and developments of multiple disorders as
276 age progressed^{1,30}. Further experiments using alternative conditional *Pten* knock-out
277 mice with Cre expression restricted to the vaginal epithelium and higher survivorship
278 will be required to address this issue.

279 *Pten* expression shifts from the suprabasal layer to the basal layer upon
280 estrogen administration as was observed in other stratified and squamous tissues. Ours
281 is the first demonstration of an estrogen-dependent role for *Pten*. *Pten* appears to
282 regulate cell proliferation in the basal layer to prevent squamous hyperplasia and/or
283 tumors in the presence of estrogens. In addition, prolonged E2 exposure induced
284 invagination of the vaginal epithelium into underlying stroma in the mutants, which
285 phenotypes are associated with vaginal and cervical cancer^{33,34}. Thus, once epithelial

286 cells undergo squamous differentiation, Pten could also function as a tumor suppressor
287 in the vagina. Intriguingly, the p63 expressing region is extended apically in the *Pten*
288 CKO mice. P63 is a marker for basal cell characteristics and is associated with
289 proliferative capacity in the stratified epithelium. Activation of Akt induces increase of
290 p63 expression and is associated with transformation of keratinocytes³⁵.

291 Our mouse model revealed several downstream effectors of PI3K/Akt in the
292 mouse vagina. One of the targets is mTOR, which showed increased phosphorylation
293 levels together with Akt phosphorylation resulting from *Pten* deletion. mTOR regulates
294 translation and cell growth as a central component of raptor (mTORC1) or rictor
295 (mTORC2) complexes via phosphorylation of their substrates (e.g., p70 ribosomal S6
296 kinase and 4E binding protein). The PI3K/Akt/mTOR pathway also represents a
297 proliferative pathway activated by PI3K and Pten loss, and contributes to the formation
298 of multiple tumor types^{30,36}. Notably, tumors involving *Pten* deletions or Akt
299 activations are highly sensitive to a specific inhibitor of mTOR, rapamycin^{37,38}. In our
300 mouse model, levels of cell proliferation, particularly in the suprabasal layers, were
301 decreased by rapamycin treatment, accompanied with partial rescue of their hyperplasia,
302 supporting a role for the Akt/mTOR pathway in the mutant phenotypes. Rapamycin
303 treatment clearly diminished cell proliferation although, mucin production in suprabasal
304 layer cells was retained. This supports the involvement of an additional alternative
305 pathway for such abnormal cell differentiation. We found MAPK activation in the
306 suprabasal cells in the mutant mouse vagina and activation of ERK1/2 has been
307 implicated for mucin production in respiratory tract, intestine and prostate²⁴⁻²⁶. This
308 supports a model wherein aberrant mucin production results from misactivation of the
309 MAPK pathway.

310 Among vaginal carcinoma, approximately 80% are squamous cell carcinomas,
311 with 13% being adenocarcinoma³⁹. There are a number of types of vaginal
312 adenocarcinoma reported, including clear cell, serous and mucinous types⁴⁰⁻⁴². The
313 histogenesis of primary vaginal adenocarcinoma, particularly which is not associated
314 with *in utero* DES exposure⁴³, is not well understood. The current results suggest a
315 contribution of the Pten/Akt/mTOR signaling pathway to the aforementioned
316 histogenesis; in particular, the vaginal mucinous adenocarcinoma might be involved in
317 MAPK signaling cascade as well. In addition, this study also showed that vaginal
318 phenotypes in the *Pten* CKO mice depend on the estrogen levels. It is currently thought
319 that excess estrogen stimulation plays a role in the etiology of hyperplasia and/or tumors
320 in female reproductive organs. However, even in the absence of estrogen, *Pten* mutation
321 induced a deleterious effect on mouse vagina. Taken together, the results presented
322 herein have important implications for treatment of lesions in the reproductive organ in
323 women.

324 Pten plays a critical role in epithelial cell homeostasis and acts as a tumor
325 suppressor in various tissues. Here we took advantage of unique features of the mouse
326 vagina as a model for analyzing the role of Pten in epithelial cell homeostasis. In the
327 absence of estrogen, Pten is expressed in the suprabasal cells where it inhibits ectopic
328 cell proliferation (Fig. 8A). In the presence of estrogen, Pten functions in the basal cells
329 where it may prevent excessive cell proliferation (Fig. 8B). Thus, Pten is indispensable
330 for homeostasis in the vaginal epithelium where its function depends on estrogen levels.
331 This provides new insight into the role of Pten in tissue homeostasis.

332

333 **Conflict of interest**

334 The authors declare no conflict of interest.

335

336 **Acknowledgements**

337 We would like to thank Dr. J. Takeda, Osaka University, Japan, for providing
338 *K5-Cre* mice. We also thank Dr. Y. Mikami, Kyoto University, Japan and Dr. Bruce
339 Blumberg, University of California, Irvine, for their support. This study was supported
340 by Grant-in-Aid for Young Scientists B, Grant-in-Aid for Scientific Research B from
341 the Ministry of Education, Culture, Sports, Science and Technology of Japan, and
342 Health Sciences Research Grant from the Ministry of Health, Labour and Welfare,
343 Japan.

344

345 **Materials and Methods**

346 *Mouse and chemical treatment*

347 C57BL/6J (CLEA, Tokyo, Japan), *K5-Cre*⁴⁴, and *Pten*-floxed mice⁴⁵ were
348 maintained under 12 h light/12 h dark at 23-25°C and fed laboratory chow (CA-1,
349 CLEA) and tap water *ad libitum*. *K5-Cre* line (B6 background) and *Pten*-floxed line
350 (*Pten*^{lox/lox}; 129 background) were crossed to produce male *K5Cre/+;Pten*^{lox/+} mice.
351 *Pten* CKO mice (*K5Cre/+;Pten*^{lox/lox}) were obtained by crossing *K5Cre/+;Pten*^{lox/+}
352 male mice and *Pten*^{lox/lox} female mice. Cre-negative and *Pten*^{lox/lox} siblings were used
353 as control. In such conditions, no prominent phenotypic variation was observed within
354 each experimental group. In most experiments, mice were ovariectomized (OVX) at 6
355 weeks of age and sacrificed at 8 weeks of age. For examining effects of estrogen, a
356 single injection of 0.1 µg 17β-estradiol (E2) (Sigma, St. Louis, MO, USA) was given to
357 OVX mice for 3 days and sacrificed 24 h after the last injection. This timing is
358 sufficient to induce stratified and fully keratinized epithelium in the mouse vagina. For
359 a long treatment, OVX mice were implanted with E2 pellets (0.01mg/ pellet, 2 months;
360 Innovative Research of America, Sarasota, FL, USA) into subcutaneous tissue for 2
361 months. Rapamycin (Toronto Research Chemicals, North York, Canada) was
362 reconstituted in DMSO at 10mg/ml then diluted in saline containing 5% PEG400
363 (Sigma) and 5% Tween-80 (Sigma). OVX mice were administrated rapamycin (1 mg/kg
364 body weight/day, i.p.) for 3 weeks. All procedures and protocols were approved by the
365 institutional animal care and use committee at the National Institute for Basic Biology.

366

367 *Histology and immunohistochemistry*

368 Hematoxylin and eosin staining was performed by a standard procedure. PAS

369 and Alcian blue staining was performed with PAS staining kit (Muto Chemical, Tokyo
370 Japan) and acidic Alcian blue. For immunohistochemistry, paraformaldehyde-fixed,
371 paraffin-embedded sections were incubated with the following primary antibodies:
372 estrogen receptor α (ER α) (H184, 1:200), p63 (4A4, 1:200, Santa Cruz, Santa Cruz,
373 CA), CK8 (1:50, Progen, Heidelberg, Germany), CK1 (1:500), CK14 (1:1000, Covance,
374 Emeryville, CA, USA), Pten (138G6, 1:100), phospho-Akt (D9E, 1:100),
375 phospho-MEK (D26, 1:160) and phospho-ERK1/2 (D13.14.4E, 1:400, Cell Signaling,
376 Danvers, MA, USA). The sections were stained with the Vectastain ABC Kit (Vector
377 Laboratories, Burlingame, CA, USA). Immunofluorescence analysis was performed
378 with Alexa Fluor protein-conjugated secondary antibodies (Life Technology, Carlsbad,
379 CA, USA). For BrdU-immunostaining, mice were injected with BrdU (Sigma) at 100
380 mg/kg body weight. One hour after the injection, tissues were collected.
381 BrdU-incorporated cells were detected with anti-BrdU antibody (1:20, Roche,
382 Mannheim, Germany). TUNEL assay for the detection of apoptotic cells was performed
383 with the *in situ* apoptosis detection kit (Roche). More than 5 animals were used for each
384 histological analysis. Error bars represent the standard error.

385

386 *Quantitative RT-PCR*

387 Total RNA (2.5 μ g), isolated with an RNeasy kit (Qiagen, Velno, Netherlands)
388 from each group, was used in RT-PCR reactions carried out with SuperScript III reverse
389 transcriptase and SYBR Green Master Mix (Life Technologies) according to
390 manufacturer's instructions. PCR conditions and sequences of primer sets are given in
391 previous report⁸. Relative RNA equivalents for each sample were obtained by
392 standardization of ribosomal protein L8 levels. More than 3 pools of samples per group

393 were run in triplicate to determine sample reproducibility. Error bars represent the
394 standard error, with all values represented as fold change compared to the control
395 treatment group normalized to an average of 1.0.

396

397 *Protein Preparation and Immunoblotting*

398 Isolated mouse vaginae were homogenized in buffer [20 mM HEPES, 2 mM
399 EDTA, 2 mM EGTA, 100 mM β -glycerophosphate, 250 mM NaCl, 1% TritonX-100,
400 protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Roche), pH 7.5]
401 and spun at 15,000 rpm for 10 min. The supernatant was collected and protein content
402 was determined using the Bradford Assay (BioRad, Hercules, CA, USA). Proteins (10
403 μ g) were electrophoresed on SDS-polyacrylamide gels and transferred onto a
404 nitrocellulose membrane. The membranes were incubated with the following primary
405 antibodies at a dilution of 1:1000 over night at 4°C: ER α (H184, Santa Cruz),
406 phospho-ER α s (2514 and 2515), mTOR (7C10), phospho-mTOR (D9C2), Akt (C67E7),
407 phospho-Akt (C31E5E and D9E, Cell Signaling). Signals were detected with the ECL
408 prime kit (GE Healthcare, Buckinghamshire, UK). Digital images were taken and
409 densitometry analysis was performed using the NIH Image J software, down loaded
410 from <http://rsbweb.nih.gov/ij/>. More than 3 pools of samples per group were used.

411

412 *Statistical analysis*

413 For BrdU-labeling and apoptotic indices, and gene expression analyses,
414 statistical analyses were performed using Student's *t*-test or Welch's *t*-test followed by
415 F-test; differences with $p < 0.05$ were considered significant.

416 **References**

- 417 1 Suzuki A, Itami S, Ohishi M, Hamada K, Inoue T, Komazawa N *et al.*
418 Keratinocyte-specific Pten deficiency results in epidermal hyperplasia,
419 accelerated hair follicle morphogenesis and tumor formation. *Cancer Res* 2003;
420 63: 674-681.
421
- 422 2 Blanco V, Keochgerian V. Cowden's syndrome. Case report, with reference to an
423 affected family. *Med Oral Patol Oral Cir Bucal* 2006; 11: E12-16.
424
- 425 3 Leao JC, Batista V, Guimaraes PB, Belo J, Porter SR. Cowden's syndrome
426 affecting the mouth, gastrointestinal, and central nervous system: a case report
427 and review of the literature. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*
428 2005; 99: 569-572.
429
- 430 4 Yoo LI, Liu DW, Le Vu S, Bronson RT, Wu H, Yuan J. Pten deficiency activates
431 distinct downstream signaling pathways in a tissue-specific manner. *Cancer Res*
432 2006; 66: 1929-1939.
433
- 434 5 Buchanan DL, Kurita T, Taylor JA, Lubahn DB, Cunha GR, Cooke PS. Role of
435 stromal and epithelial estrogen receptors in vaginal epithelial proliferation,
436 stratification, and cornification. *Endocrinology* 1998; 139: 4345-4352.
437
- 438 6 Cooke PS, Buchanan DL, Young P, Setiawan T, Brody J, Korach KS *et al.*
439 Stromal estrogen receptors mediate mitogenic effects of estradiol on uterine
440 epithelium. *Proc Natl Acad Sci U S A* 1997; 94: 6535-6540.
441
- 442 7 Nelson KG, Sakai Y, Eitzman B, Steed T, McLachlan J. Exposure to
443 diethylstilbestrol during a critical developmental period of the mouse
444 reproductive tract leads to persistent induction of two estrogen-regulated genes.
445 *Cell Growth Differ* 1994; 5: 595-606.
446
- 447 8 Miyagawa S, Katsu Y, Watanabe H, Iguchi T. Estrogen-independent activation
448 of erbBs signaling and estrogen receptor alpha in the mouse vagina exposed
449 neonatally to diethylstilbestrol. *Oncogene* 2004; 23: 340-349.
450
- 451 9 Miyagawa S, Suzuki A, Katsu Y, Kobayashi M, Goto M, Handa H *et al.*
452 Persistent gene expression in mouse vagina exposed neonatally to
453 diethylstilbestrol. *J Mol Endocrinol* 2004; 32: 663-677.
454
- 455 10 Ghahary A, Chakrabarti S, Murphy LJ. Localization of the sites of synthesis and
456 action of insulin-like growth factor-I in the rat uterus. *Mol Endocrinol* 1990; 4:
457 191-195.
458
- 459 11 Ignar-Trowbridge DM, Nelson KG, Bidwell MC, Curtis SW, Washburn TF,
460 McLachlan JA *et al.* Coupling of dual signaling pathways: epidermal growth
461 factor action involves the estrogen receptor. *Proc Natl Acad Sci U S A* 1992; 89:

- 462 4658-4662.
- 463
- 464 12 Nelson KG, Takahashi T, Bossert NL, Walmer DK, McLachlan JA. Epidermal
465 growth factor replaces estrogen in the stimulation of female genital-tract growth
466 and differentiation. *Proc Natl Acad Sci U S A* 1991; 88: 21-25.
- 467
- 468 13 Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP *et al.*
469 Conditional loss of uterine Pten unfailingly and rapidly induces endometrial
470 cancer in mice. *Cancer Res* 2008; 68: 5619-5627.
- 471
- 472 14 Joshi A, Ellenson LH. Adenovirus mediated homozygous endometrial epithelial
473 Pten deletion results in aggressive endometrial carcinoma. *Exp Cell Res* 2011;
474 317: 1580-1589.
- 475
- 476 15 Kim TH, Franco HL, Jung SY, Qin J, Broaddus RR, Lydon JP *et al.* The
477 synergistic effect of Mig-6 and Pten ablation on endometrial cancer development
478 and progression. *Oncogene* 2010; 29: 3770-3780.
- 479
- 480 16 Memarzadeh S, Zong Y, Janzen DM, Goldstein AS, Cheng D, Kurita T *et al.*
481 Cell-autonomous activation of the PI3-kinase pathway initiates endometrial
482 cancer from adult uterine epithelium. *Proc Natl Acad Sci U S A* 2010; 107:
483 17298-17303.
- 484
- 485 17 Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human
486 cytokeratins: patterns of expression in normal epithelia, tumors and cultured
487 cells. *Cell* 1982; 31: 11-24.
- 488
- 489 18 Gimenez-Conti IB, Lynch M, Roop D, Bhowmik S, Majeski P, Conti CJ.
490 Expression of keratins in mouse vaginal epithelium. *Differentiation* 1994; 56:
491 143-151.
- 492
- 493 19 Yang A, Schweitzer R, Sun D, Kaghad M, Walker N, Bronson RT *et al.* p63 is
494 essential for regenerative proliferation in limb, craniofacial and epithelial
495 development. *Nature* 1999; 398: 714-718.
- 496
- 497 20 Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR, Bradley A. p63 is a p53
498 homologue required for limb and epidermal morphogenesis. *Nature* 1999; 398:
499 708-713.
- 500
- 501 21 Bodine SC, Stitt TN, Gonzalez M, Kline WO, Stover GL, Bauerlein R *et al.*
502 Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and
503 can prevent muscle atrophy in vivo. *Nat Cell Biol* 2001; 3: 1014-1019.
- 504
- 505 22 Rommel C, Bodine SC, Clarke BA, Rossman R, Nunez L, Stitt TN *et al.*
506 Mediation of IGF-1-induced skeletal myotube hypertrophy by
507 PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways. *Nat Cell Biol* 2001; 3:
508 1009-1013.

- 509
510 23 Pende M, Kozma SC, Jaquet M, Oorschot V, Burcelin R, Le Marchand-Brustel
511 Y *et al.* Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in
512 S6K1-deficient mice. *Nature* 2000; 408: 994-997.
513
514 24 Kurita T, Medina RT, Mills AA, Cunha GR. Role of p63 and basal cells in the
515 prostate. *Development* 2004; 131: 4955-4964.
516
517 25 Lee HW, Ahn DH, Crawley SC, Li JD, Gum JR, Jr., Basbaum CB *et al.* Phorbol
518 12-myristate 13-acetate up-regulates the transcription of MUC2 intestinal mucin
519 via Ras, ERK, and NF-kappa B. *J Biol Chem* 2002; 277: 32624-32631.
520
521 26 Li JD, Feng W, Gallup M, Kim JH, Gum J, Kim Y *et al.* Activation of
522 NF-kappaB via a Src-dependent Ras-MAPK-pp90rsk pathway is required for
523 *Pseudomonas aeruginosa*-induced mucin overproduction in epithelial cells. *Proc*
524 *Natl Acad Sci U S A* 1998; 95: 5718-5723.
525
526 27 Vilgelm A, Lian Z, Wang H, Beuparlant SL, Klein-Szanto A, Ellenson LH *et al.*
527 Akt-mediated phosphorylation and activation of estrogen receptor alpha is
528 required for endometrial neoplastic transformation in *Pten*^{+/-} mice. *Cancer Res*
529 2006; 66: 3375-3380.
530
531 28 Lannigan DA. Estrogen receptor phosphorylation. *Steroids* 2003; 68: 1-9.
532
533 29 Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri
534 H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor
535 alpha: a new model for anti-estrogen resistance. *J Biol Chem* 2001; 276:
536 9817-9824.
537
538 30 Squarize CH, Castilho RM, Gutkind JS. Chemoprevention and treatment of
539 experimental Cowden's disease by mTOR inhibition with rapamycin. *Cancer*
540 *Res* 2008; 68: 7066-7072.
541
542 31 Klotz DM, Hewitt SC, Ciana P, Raviscioni M, Lindzey JK, Foley J *et al.*
543 Requirement of estrogen receptor-alpha in insulin-like growth factor-1
544 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen
545 receptor cross-talk. *J Biol Chem* 2002; 277: 8531-8537.
546
547 32 Joshi A, Wang H, Jiang G, Douglas W, Chan JS, Korach KS *et al.* Endometrial
548 tumorigenesis in *Pten*(^{+/-}) mice is independent of coexistence of estrogen and
549 estrogen receptor alpha. *Am J Pathol* 2012; 180: 2536-2547.
550
551 33 Brake T, Lambert PF. Estrogen contributes to the onset, persistence, and
552 malignant progression of cervical cancer in a human papillomavirus-transgenic
553 mouse model. *Proc Natl Acad Sci U S A* 2005; 102: 2490-2495.
554
555 34 Ozawa S, Iguchi T, Sawada K, Ohta Y, Takasugi N, Bern HA. Postnatal vaginal

556 nodules induced by prenatal diethylstilbestrol treatment correlate with later
557 development of ovary-independent vaginal and uterine changes in mice. *Cancer*
558 *Lett* 1991; 58: 167-175.

559

560 35 Segrelles C, Moral M, Lara MF, Ruiz S, Santos M, Leis H *et al.* Molecular
561 determinants of Akt-induced keratinocyte transformation. *Oncogene* 2006; 25:
562 1174-1185.

563

564 36 Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell
565 growth. *Nature* 2006; 441: 424-430.

566

567 37 Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM *et al.*
568 mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia
569 through regulation of apoptotic and HIF-1-dependent pathways. *Nat Med* 2004;
570 10: 594-601.

571

572 38 Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R *et al.*
573 Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.
574 *Proc Natl Acad Sci U S A* 2001; 98: 10314-10319.

575

576 39 Platz CE, Benda JA. Female genital tract cancer. *Cancer* 1995; 75: 270-294.

577

578 40 Mudhar HS, Smith JH, Tidy J. Primary vaginal adenocarcinoma of intestinal
579 type arising from an adenoma: case report and review of the literature. *Int J*
580 *Gynecol Pathol* 2001; 20: 204-209.

581

582 41 McCluggage WG, Price JH, Dobbs SP. Primary adenocarcinoma of the vagina
583 arising in endocervicosis. *Int J Gynecol Pathol* 2001; 20: 399-402.

584

585 42 Ebrahim S, Daponte A, Smith TH, Tiltman A, Guidozi F. Primary mucinous
586 adenocarcinoma of the vagina. *Gynecol Oncol* 2001; 80: 89-92.

587

588 43 Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina.
589 Association of maternal stilbestrol therapy with tumor appearance in young
590 women. *N Engl J Med* 1971; 284: 878-881.

591

592 44 Tarutani M, Itami S, Okabe M, Ikawa M, Tezuka T, Yoshikawa K *et al.*
593 Tissue-specific knockout of the mouse *Pig-a* gene reveals important roles for
594 GPI-anchored proteins in skin development. *Proc Natl Acad Sci U S A* 1997; 94:
595 7400-7405.

596

597 45 Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, Zack JA *et*
598 *al.* Negative regulation of neural stem/progenitor cell proliferation by the *Pten*
599 tumor suppressor gene in vivo. *Science* 2001; 294: 2186-2189.

600

601

602

604 **Figure legend**

605 **Fig. 1.** Epithelium-specific deletion of *Pten* in mouse vagina. *Pten* is predominantly
606 expressed in the basal cells in the E2-administrated control mouse vagina (A), whereas
607 *Pten* is exclusively expressed in the suprabasal cells in the control OVX mice (B). In
608 both E2-administrated and OVX *Pten* CKO mouse vagina, *Pten* expression is not
609 detected in the epithelium (C, D). Scale bar: 100 μ m.

610

611 **Fig. 2.** Effect of epithelial cell-specific inactivation of *Pten* on the mouse vagina. The
612 vaginal epithelium of 8-week-old ovariectomized (OVX) control (A) and *Pten* CKO
613 mice (B). Some parts of the *Pten* CKO vagina exhibit severe hyperplastic phenotypes
614 with multiple abnormal gland-like pits (B'). PAS (C, D) and Alcian blue staining (E, F)
615 indicate mucin production in the control (C, E) and *Pten* CKO vagina (D, F). E2
616 administration induces stratification and keratinized differentiation in the control (G)
617 and *Pten* CKO mice (H). The epithelium in the *Pten* CKO mice administrated with E2
618 is thicker than that of controls (I). The recurring abnormal phenotypes of vagina in *Pten*
619 CKO mice at 2 weeks after the last E2 administration (J; n=4). Prolonged E2 exposure
620 results in papillomatosis, invagination of the vaginal epithelium into underlying stroma
621 in the CKO mice (K, L; n=4). Scale bar: 100 μ m.

622

623 **Fig. 3.** Expression pattern of cell differentiation marker in mouse vagina.
624 Immunohistochemical staining for CK14 (A, B, I, J), CK1 (C, D, K, L), CK8 (E, F, M,
625 N) and p63 (G, H, O, P). In OVX *Pten* CKO mice, an undifferentiating cell marker CK8
626 is expressed but a stratified and squamous differentiating cell marker CK1 is not (C-F),
627 suggesting undifferentiation status of the epithelia. p63 expression is only expressed in